Colin J Rog, Shelby Reiter, Evan S Ong and Mohamed Alassas*
Department of General Surgery, Division of Surgical Oncology, Swedish Medical Center, USAFulltext PDF
Malignant peritoneal mesothelioma is a rare malignancy with a generally poor prognosis. For patients with resectable disease, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy offers the best chance of overall survival. However, in patients with initially unresectable disease, chemotherapy with pemetrexed and cisplatin remains the only treatment option. In some cases, up-front chemotherapy will enhance a patient’s resectability, making the patient a surgical candidate. Complete pathological response is an extremely rare outcome with only a handful of cases reported in recent literature. We report a case of a 44-year-old male patient with initially unresectable malignant peritoneal mesothelioma who received pemetrexed and cisplatin with good response and then underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, demonstrating complete pathologic response on final pathology. This is a rare case that may provide helpful insight into the successful treatment of initially unresectable malignant peritoneal mesothelioma.
Rog CJ, Reiter S, Ong ES, Alassas M. A Rare Case of Peritoneal Mesothelioma with Complete Pathological Response
after Treatment with Pemetrexed/Cisplatin and Cytoreductive Surgery with HIPEC. Surg Oncol Clin Pract J. 2020;3(1):1013..